Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

ProBioGen, Life Technologies' new cell line development kits now available for biologic drug production

Life Technologies Corporation and ProBioGen AG today announced the availability of Gibco Freedom Cell Line Development Kits, a new line of royalty-free products that integrate cells, reagents, culture media and protocols to bring simplicity and flexibility, eliminating up to two months in the earliest stages of new biological drug development.

17 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Poland

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie, Warsaw, Poland, the first clinical site in Poland and the first center in the EU.

13 May 2011

GSK, AstraZeneca and University of Manchester create new collaborative centre for inflammation research

The University of Manchester, GlaxoSmithKline and AstraZeneca announce today the creation of the Manchester Collaborative Centre for Inflammation Research, a unique collaboration to establish a world-leading translational centre for inflammatory diseases. The project starts out with an initial investment of -5M from each partner over a three year period.

From The University of Manchester 12 May 2011

Journal of Rheumatology publishes positive results from Cimzia Phase III trial in RA

UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis patients treated with Cimzia, the only approved PEGylated anti-TNF, together with methotrexate, achieved a rapid response associated with improved long-term outcomes one year after treatment began.

11 May 2011

Pepscan, Phylogica collaborate for Phylomer peptide lead optimisation

Phylogica Ltd, a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

10 May 2011

Charisela develops breakthrough adiponectin assay

Charisela Technologies, Inc., a manufacturer of advanced assays for flow cytometers, announced today that it has developed an adiponectin assay with major advantages over existing technologies, including the elimination of dilutions. Adiponectin (Acrp30), an adipocytokine, is important in many therapeutic arenas, including type 2 diabetes, obesity, atherosclerosis, and rheumatoid arthritis.

9 May 2011

Antares Pharma first quarter total revenues increase to $3.6 million

Antares Pharma, Inc. today reported financial and operating results for the first quarter ended March 31, 2011.

9 May 2011

POZEN reports revenue of $4.5 million for first quarter 2011

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2011.

5 May 2011

Grant Thornton Leader & Innovator of the Year award for Diplomat Specialty Pharmacy president

Phil Hagerman, president and CEO of Diplomat Specialty Pharmacy in Flint, has been named Grant Thornton Leader & Innovator of the Year.

30 Apr 2011

Merck first quarter sales increase 1% to $11.6 billion for 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2011.

30 Apr 2011

Health Canada grants SQI license to market IgX PLEX Celiac Panel

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced it has received a license from Health Canada permitting the Company to market its IgX PLEX™ Celiac Panel, a quantitative 4-plex panel, which will run on SQI's automated SQiDworks™ Diagnostics Platform.

29 Apr 2011

MorphoSys reaches second clinical milestone with OncoMed Pharmaceuticals

MorphoSys AG announced today that it has received a milestone payment from OncoMed Pharmaceuticals in connection with the FDA acceptance of an IND for a HuCAL-derived, fully human antibody. The antibody OMP-18R5, which targets the Wnt signaling pathway, will be evaluated in a Phase 1 trial in the US in patients with advanced solid tumors.

29 Apr 2011

Top-line results from Pfizer's tofacitinib Phase 3 studies in RA

Pfizer Inc. announced today top-line results from the ORAL Standard and ORAL Step Phase 3 studies of tofacitinib, an investigational, novel, oral JAK inhibitor.

29 Apr 2011

CEL-SCI initiates Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, at the Meenakshi Mission Hospital and Research Centre in Madurai, Tamil Nadu, India, the first clinical site in India.

28 Apr 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Blood levels of inflammation-controlling protein linked to childrens' risk of developing diabetes

Decreasing blood levels of a protein that helps control inflammation may be a red flag that could help children avoid type 1 diabetes, researchers say.

28 Apr 2011

Positive results from Sanofi-aventis and Regeneron ZALTRAP Phase III study in mCRC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP, also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival in the second-line treatment of metastatic colorectal cancer.

27 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

POZEN, AstraZeneca file lawsuit against Dr. Reddy's for patent infringement relating to VIMOVO

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it and AstraZeneca filed a lawsuit against Dr. Reddy's Laboratories (Dr. Reddy's) in the United States District Court for the District of New Jersey, for infringement of U.S. Patent No. 6,926,907 relating to VIMOVO™ (naproxen / esomeprazole magnesium) delayed-release tablets.

25 Apr 2011